BridgeBio Pharma, Inc. (BBIO) vs Madrigal Pharmaceuticals, Inc. (MDGL)

BridgeBio Pharma, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $13.1B against $11.9B — 1.1× the size. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 149.0%. Madrigal Pharmaceuticals, Inc. has the higher net margin (−25.3% vs −97.0%) and the lower return on invested capital (−787.3% vs 0.00%). Across the 16 metrics below, Madrigal Pharmaceuticals, Inc. leads on 10 and BridgeBio Pharma, Inc. on 6.

Valuation

Metric BBIO MDGL Biotechnology median
P/E n/m n/m 7.88
P/S 18.00 11.73 11.47
P/B n/m 28.75 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 19.70 11.34 10.73
Earnings yield (5.45%) (2.50%) (28.84%)
Free cash flow yield (3.46%) (1.39%) (23.03%)

Profitability

Metric BBIO MDGL Biotechnology median
Gross margin 94.44% 91.48% 65.16%
Operating margin (69.81%) (25.13%) 0.00%
Net margin (97.03%) (25.32%) 0.00%
Free cash flow margin (61.06%) (16.07%) 0.00%
Return on equity 32.31% (53.31%) (57.72%)
Return on assets (60.23%) (28.77%) (49.22%)
Return on invested capital 0.00% (787.33%) 0.00%

Growth

Metric BBIO MDGL Biotechnology median
Revenue growth (TTM) 202.39% 149.04% 5.64%
EPS growth (last fiscal year) (31.25%) 41.32% —
Revenue growth, 5-year CAGR 127.44% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BBIO MDGL Biotechnology median
Debt to equity (0.77) 0.65 0.00
Current ratio 1.23 3.20 4.73
Net debt to EBITDA (2.47) 2.21 0.96

Dividend

Metric BBIO MDGL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BBIO MDGL Biotechnology median
Market cap 13.10b 11.86b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack